iCo Therapeutics Announces Poster Presentation at ARVO

VANCOUVER, April 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that research collaborators will make a poster presentation at the Association for Research in Vision and Ophthalmology 2014 Annual Meeting. The Meeting is being held from May 4^th - 8^th, 2014 in Orlando, Florida.

"The data being presented outlines patient demographics and baseline characteristics of each arm of the phase two iDEAL study, as well as the trial design and objectives," said Peter Hnik, MD, Chief Medical Officer of iCo Therapeutics.  "The poster provides a great context to the upcoming phase two study's primary data at month eight and secondary data at month 12."

"More treatment options are needed for individuals with diabetic macular edema" said Helen Nickerson, Ph. D., Senior Scientific Program Manager for Complications Therapies at JDRF.  "JDRF is pleased to collaborate in the iDEAL study and grateful to the investigators, physicians and patients involved. We eagerly anticipate results from this important study." 

The poster, titled "Demographics and Baseline Characteristics of the iDEAL Study: A Randomized, Multi-center, Phase II Study of the safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCO-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the FoveAL Center" is being presented by Dr. Quan Dong Nguyen et al and will be presented from 11:00 am ET - 12:45 pm ET on Monday, May 5.  The poster presents the design, demographics, and baseline characteristics of the iDEAL Study, as well as the inclusion/exclusion criteria and characteristics by randomized treatment group.

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research.  JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D.  JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.  As the largest charitable supporter of T1D research, JDRF is currently sponsoring $568 million in scientific research in 17 countries. For more information, please visit www.jdrf.org.

About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. iCo trades on the TSX Venture Exchange under the symbol "ICO" and the OTCQX under the symbol "ICOTF". For more information, visit the Company website at: www.icotherapeutics.com.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements
Certain statements included in this press release may be considered forward-looking statements" within the meaning of applicable securities laws.  Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will," and similar references to future periods and includes, but is not limited to, statements about the intended use of proceeds of the Offering. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE iCo Therapeutics Inc.